Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B

Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B

Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in na?ve patients with CHB were investigated. Methods: In this retrospective study, 152 na?ve Korean patients with CHB who received 30 mg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut and liver 2012-10, Vol.6 (4), p.486
Hauptverfasser: Bum Su Choung, In Hee Kim, Byung Jun Jeon, Seok Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim
Format: Artikel
Sprache:kor
Schlagworte:
2`-Fluoro-5-methylarabinosyl-uracil
Chronic hepatitis B
Muscular diseases
Viral breakthrough
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 486
container_title Gut and liver
container_volume 6
creator Bum Su Choung
In Hee Kim
Byung Jun Jeon
Seok Lee
Seong Hun Kim
Sang Wook Kim
Seung Ok Lee
Soo Teik Lee
Dae Ghon Kim
description Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in na?ve patients with CHB were investigated. Methods: In this retrospective study, 152 na?ve Korean patients with CHB who received 30 mg of CLV once daily for at least 12 months were investigated. Results: The cumulative rates at months 12, 24, and 36, respectively, were 65.8%, 74.7%, and 74.7% for undetectable serum hepatitis B virus (HBV) DNA (
format Article
fullrecord <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3115362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3115362</kiss_id><sourcerecordid>3115362</sourcerecordid><originalsourceid>FETCH-kiss_primary_31153623</originalsourceid><addsrcrecordid>eNp9i8sKgkAUQGdRkD2-oM39AcEHaa2CxHARETT7uNidvKWjzEyGf5-L1q0OnMOZCC_cpYkfRdt4JubWPoMgCaN044nHqdUPX5JpQBpC15B2kCvFJZYDoL7DFRW5AVoFWU39-86aQFZksBuANZxx3xNc0PF4WviwqyCrTKu5hIK60Tu2cFiKqcLa0urHhVgfc5kV_outvXWGGzTDLQ7DTZxE8f_6BZdHQB0</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B</title><source>KoreaMed Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Bum Su Choung ; In Hee Kim ; Byung Jun Jeon ; Seok Lee ; Seong Hun Kim ; Sang Wook Kim ; Seung Ok Lee ; Soo Teik Lee ; Dae Ghon Kim</creator><creatorcontrib>Bum Su Choung ; In Hee Kim ; Byung Jun Jeon ; Seok Lee ; Seong Hun Kim ; Sang Wook Kim ; Seung Ok Lee ; Soo Teik Lee ; Dae Ghon Kim</creatorcontrib><description>Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in na?ve patients with CHB were investigated. Methods: In this retrospective study, 152 na?ve Korean patients with CHB who received 30 mg of CLV once daily for at least 12 months were investigated. Results: The cumulative rates at months 12, 24, and 36, respectively, were 65.8%, 74.7%, and 74.7% for undetectable serum hepatitis B virus (HBV) DNA (&lt;12 IU/mL); 77.6%, 86.2%, and 86.2% for normalization of serum alanine aminotransferase (&lt;40 IU/L); 17.6%, 23.5%, and 23.5% for hepatitis B e antigen (HBeAg) loss or seroconversion; and 6.6%, 22.5%, and 30.0% for viral breakthrough. HBeAg positivity (p=0.010), baseline serum HBV DNA level ≥6 log10 IU/mL (p=0.032) and detectable serum HBV DNA (≥12 IU/mL) at week 24 (p=0.023) were independently associated with the development of viral breakthrough. During follow-up, CLV-induced myopathy developed in 5.9% of patients. Conclusions: The results of long-term CLV therapy for the treatment of na?ve patients with CHB showed a high frequency of antiviral resistance and substantial associated myopathy. Therefore, we advise that CLV should not be used as a first-line treatment for na?ve patients given the availability of other more potent, safer antiviral agents. (Gut Liver 2012;6:486-492)</description><identifier>ISSN: 1976-2283</identifier><language>kor</language><publisher>대한간학회</publisher><subject>2`-Fluoro-5-methylarabinosyl-uracil ; Chronic hepatitis B ; Muscular diseases ; Viral breakthrough</subject><ispartof>Gut and liver, 2012-10, Vol.6 (4), p.486</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Bum Su Choung</creatorcontrib><creatorcontrib>In Hee Kim</creatorcontrib><creatorcontrib>Byung Jun Jeon</creatorcontrib><creatorcontrib>Seok Lee</creatorcontrib><creatorcontrib>Seong Hun Kim</creatorcontrib><creatorcontrib>Sang Wook Kim</creatorcontrib><creatorcontrib>Seung Ok Lee</creatorcontrib><creatorcontrib>Soo Teik Lee</creatorcontrib><creatorcontrib>Dae Ghon Kim</creatorcontrib><title>Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B</title><title>Gut and liver</title><addtitle>Gut and Liver</addtitle><description>Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in na?ve patients with CHB were investigated. Methods: In this retrospective study, 152 na?ve Korean patients with CHB who received 30 mg of CLV once daily for at least 12 months were investigated. Results: The cumulative rates at months 12, 24, and 36, respectively, were 65.8%, 74.7%, and 74.7% for undetectable serum hepatitis B virus (HBV) DNA (&lt;12 IU/mL); 77.6%, 86.2%, and 86.2% for normalization of serum alanine aminotransferase (&lt;40 IU/L); 17.6%, 23.5%, and 23.5% for hepatitis B e antigen (HBeAg) loss or seroconversion; and 6.6%, 22.5%, and 30.0% for viral breakthrough. HBeAg positivity (p=0.010), baseline serum HBV DNA level ≥6 log10 IU/mL (p=0.032) and detectable serum HBV DNA (≥12 IU/mL) at week 24 (p=0.023) were independently associated with the development of viral breakthrough. During follow-up, CLV-induced myopathy developed in 5.9% of patients. Conclusions: The results of long-term CLV therapy for the treatment of na?ve patients with CHB showed a high frequency of antiviral resistance and substantial associated myopathy. Therefore, we advise that CLV should not be used as a first-line treatment for na?ve patients given the availability of other more potent, safer antiviral agents. (Gut Liver 2012;6:486-492)</description><subject>2`-Fluoro-5-methylarabinosyl-uracil</subject><subject>Chronic hepatitis B</subject><subject>Muscular diseases</subject><subject>Viral breakthrough</subject><issn>1976-2283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9i8sKgkAUQGdRkD2-oM39AcEHaa2CxHARETT7uNidvKWjzEyGf5-L1q0OnMOZCC_cpYkfRdt4JubWPoMgCaN044nHqdUPX5JpQBpC15B2kCvFJZYDoL7DFRW5AVoFWU39-86aQFZksBuANZxx3xNc0PF4WviwqyCrTKu5hIK60Tu2cFiKqcLa0urHhVgfc5kV_outvXWGGzTDLQ7DTZxE8f_6BZdHQB0</recordid><startdate>20121030</startdate><enddate>20121030</enddate><creator>Bum Su Choung</creator><creator>In Hee Kim</creator><creator>Byung Jun Jeon</creator><creator>Seok Lee</creator><creator>Seong Hun Kim</creator><creator>Sang Wook Kim</creator><creator>Seung Ok Lee</creator><creator>Soo Teik Lee</creator><creator>Dae Ghon Kim</creator><general>대한간학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20121030</creationdate><title>Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B</title><author>Bum Su Choung ; In Hee Kim ; Byung Jun Jeon ; Seok Lee ; Seong Hun Kim ; Sang Wook Kim ; Seung Ok Lee ; Soo Teik Lee ; Dae Ghon Kim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_31153623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2012</creationdate><topic>2`-Fluoro-5-methylarabinosyl-uracil</topic><topic>Chronic hepatitis B</topic><topic>Muscular diseases</topic><topic>Viral breakthrough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bum Su Choung</creatorcontrib><creatorcontrib>In Hee Kim</creatorcontrib><creatorcontrib>Byung Jun Jeon</creatorcontrib><creatorcontrib>Seok Lee</creatorcontrib><creatorcontrib>Seong Hun Kim</creatorcontrib><creatorcontrib>Sang Wook Kim</creatorcontrib><creatorcontrib>Seung Ok Lee</creatorcontrib><creatorcontrib>Soo Teik Lee</creatorcontrib><creatorcontrib>Dae Ghon Kim</creatorcontrib><collection>Korea Information Science Society (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Gut and liver</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bum Su Choung</au><au>In Hee Kim</au><au>Byung Jun Jeon</au><au>Seok Lee</au><au>Seong Hun Kim</au><au>Sang Wook Kim</au><au>Seung Ok Lee</au><au>Soo Teik Lee</au><au>Dae Ghon Kim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B</atitle><jtitle>Gut and liver</jtitle><addtitle>Gut and Liver</addtitle><date>2012-10-30</date><risdate>2012</risdate><volume>6</volume><issue>4</issue><spage>486</spage><pages>486-</pages><issn>1976-2283</issn><abstract>Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in na?ve patients with CHB were investigated. Methods: In this retrospective study, 152 na?ve Korean patients with CHB who received 30 mg of CLV once daily for at least 12 months were investigated. Results: The cumulative rates at months 12, 24, and 36, respectively, were 65.8%, 74.7%, and 74.7% for undetectable serum hepatitis B virus (HBV) DNA (&lt;12 IU/mL); 77.6%, 86.2%, and 86.2% for normalization of serum alanine aminotransferase (&lt;40 IU/L); 17.6%, 23.5%, and 23.5% for hepatitis B e antigen (HBeAg) loss or seroconversion; and 6.6%, 22.5%, and 30.0% for viral breakthrough. HBeAg positivity (p=0.010), baseline serum HBV DNA level ≥6 log10 IU/mL (p=0.032) and detectable serum HBV DNA (≥12 IU/mL) at week 24 (p=0.023) were independently associated with the development of viral breakthrough. During follow-up, CLV-induced myopathy developed in 5.9% of patients. Conclusions: The results of long-term CLV therapy for the treatment of na?ve patients with CHB showed a high frequency of antiviral resistance and substantial associated myopathy. Therefore, we advise that CLV should not be used as a first-line treatment for na?ve patients given the availability of other more potent, safer antiviral agents. (Gut Liver 2012;6:486-492)</abstract><pub>대한간학회</pub><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1976-2283
ispartof Gut and liver, 2012-10, Vol.6 (4), p.486
issn 1976-2283
language kor
recordid cdi_kiss_primary_3115362
source KoreaMed Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects 2`-Fluoro-5-methylarabinosyl-uracil
Chronic hepatitis B
Muscular diseases
Viral breakthrough
title Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Na?ve Patients with Chronic Hepatitis B
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A29%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Treatment%20Efficacy%20and%20Safety%20of%20Clevudine%20Therapy%20in%20Na?ve%20Patients%20with%20Chronic%20Hepatitis%20B&rft.jtitle=Gut%20and%20liver&rft.au=Bum%20Su%20Choung&rft.date=2012-10-30&rft.volume=6&rft.issue=4&rft.spage=486&rft.pages=486-&rft.issn=1976-2283&rft_id=info:doi/&rft_dat=%3Ckiss%3E3115362%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3115362&rfr_iscdi=true